Author:
Pfaller Michael A.,Andes David,Arendrup Maiken C.,Diekema Daniel J.,Espinel-Ingroff Ana,Alexander Barbara D.,Brown Steven D.,Chaturvedi Vishnu,Fowler Cynthia L.,Ghannoum Mahmoud A.,Johnson Elizabeth M.,Knapp Cynthia C.,Motyl Mary R.,Ostrosky-Zeichner Luis,Walsh Thomas J.
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference73 articles.
1. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole;Alexander;Transplantation,2005
2. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients;Ally;Clin. Infect. Dis.,2001
3. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model;Andes;Antimicrob. Agents Chemother.,2003
4. Does one voriconazole breakpoint suit all Candida species?;Arendrup;J. Clin. Microbiol.,2007
5. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species;Arendrup;Antimicrob. Agents Chemother.,2009
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献